84 related articles for article (PubMed ID: 14671387)
1. Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma.
Zornitzki T; Knobler H; Nass D; Hadani M; Shimon I
Horm Res; 2004; 61(3):111-6. PubMed ID: 14671387
[TBL] [Abstract][Full Text] [Related]
2. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
[TBL] [Abstract][Full Text] [Related]
3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
4. Gender-related differences in prolactinomas. A clinicopathological study.
Schaller B
Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
[TBL] [Abstract][Full Text] [Related]
5. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
6. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
7. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
8. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
Tng EL; Teo AE; Aung AT
J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797
[TBL] [Abstract][Full Text] [Related]
9. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
[TBL] [Abstract][Full Text] [Related]
10. Malignant prolactinoma: a rare case report.
Trivedi P; Gupta A; Pasricha S; Patel D
Neurol India; 2010; 58(5):778-80. PubMed ID: 21045511
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract][Full Text] [Related]
12. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
13. The role of Ki-67 in women with a resistant prolactinoma: a retrospective analysis in 199 hospitalized patients over a period of 5 years.
Lu C; Ren Z; Huan C; Cui G
Pak J Pharm Sci; 2014 Jul; 27(4 Suppl):1075-81. PubMed ID: 25016269
[TBL] [Abstract][Full Text] [Related]
14. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
15. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
Hamester U; Saeger W; Lüdecke DK
Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
[TBL] [Abstract][Full Text] [Related]
16. Metastasising pituitary neuroendocrinal tumour with peptide secretion.
Harinarayan CV; Reddy K
J Assoc Physicians India; 2004 Jan; 52():74-5. PubMed ID: 15633727
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma surgery.
Jan M; Dufour H; Brue T; Jaquet P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
19. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]